Filters








628 Hits in 1.5 sec

Rebuttal from Dr Nestle and Dr Belderbos

Ursula Nestle, José Belderbos
2015 Translational Lung Cancer Research  
doi:10.3978/j.issn.2218-6751.2015.08.06 pmid:26629434 pmcid:PMC4630532 fatcat:34ngpuzdy5ch5mburv4ecjghqq

"Nur eine Planung …"

Stefan Delorme, Ursula Nestle, Neil Burnet
2018 Der Radiologe (Berlin. Print)  
doi:10.1007/s00117-018-0429-x pmid:30088038 fatcat:hnph4fkm3zagzanovpslpjny6y

Molekulare Diagnostik und Bildgebung

Christian Fink, Annette Fisseler-Eckhoff, Ralf Huss, Ursula Nestle
2009 Onkologie (Basel)  
Ursächlich hierfür waren vor allem die bessere Dif- 6 Onkologie 2009;32(suppl 1):3-8 Fink/Fisseler-Eckhoff/Huss/Nestle Abb. 2.  ...  Arzneimittel dürften zukünftig molekulare Biomarker leisten, mit denen Tumo- ren früher diagnostiziert, die spezifischen Tumoreigenschaften ge- 4 Onkologie 2009;32(suppl 1):3-8 Fink/Fisseler-Eckhoff/Huss/Nestle  ... 
doi:10.1159/000215715 pmid:19521129 fatcat:ul4yirv4t5eyxamipjuwvltp54

Simultaneous integrated protection

Thomas B. Brunner, Ursula Nestle, Sonja Adebahr, Eleni Gkika, Rolf Wiehle, Dimos Baltas, Anca-Ligia Grosu
2016 Strahlentherapie und Onkologie (Print)  
Brunner and Ursula Nestle contributed equally to the manuscript. Electronic supplementary material The online version of this article (12 fractions in 1, 3, 1, and 1 patients, respectively.  ...  Nestle, S. Adebahr, E. Gkika, R. Wiehle, D. Baltas, and A.-L. Grosu declare that they have no competing interest. dose constraint values shown in Supplemental Table 1 (p = 0.001, Wilcoxon test).  ... 
doi:10.1007/s00066-016-1057-x pmid:27757502 pmcid:PMC5122615 fatcat:2n7t4sihczbjxpdghv6naangqu

Detection of MRSA ST3061-t843-mecCand ST398-t011-mecAin white stork nestlings exposed to human residues: Table 1

Paula Gómez, Carmen Lozano, Mari Cruz Camacho, José-Francisco Lima-Barbero, José-Manuel Hernández, Myriam Zarazaga, Úrsula Höfle, Carmen Torres
2015 Journal of Antimicrobial Chemotherapy  
The prevalence of S. aureus was higher in nestlings from landfills (24/43, 55.8%) than in those from natural habitats (8/49, 16.3%).  ...  Methods: Tracheal samples from 92 stork nestlings of two landfill-associated and two natural-habitat colonies were inoculated in specific media for S. aureus and MRSA recovery.  ...  Forty-three nestlings were tested at colonies 3 or 4, which were associated with foraging of the adults at landfill sites.  ... 
doi:10.1093/jac/dkv314 pmid:26490014 fatcat:eamn3ceyn5g25ivxiajxnxnlvi

EORTC Imaging Group

Nandita DeSouza, Otto S. Hoekstra, Ursula Nestle, Sigrid Stroobants, Ronald Boellaard, Cornelia Schaefer-Prokop, Lalitha Shankar, Liisa Pylkkanen, Ivalina Hristova, John Bean
2012 EJC Supplements  
Imaging data have the potential to provide information on disease profiling pertaining to diagnosis, prognosis, selection of therapy, monitoring of response to therapy and pharmacokinetic information of drugs. Selection of the most appropriate imaging modality for a specific task will be vital for diagnosis, stratification, treatment response or treatment efficacy, toxicity assessment, and treatment outcome measures (progression-free survival). The EORTC Imaging Group was formed to establish
more » ... maintain the scientific and clinical value of advanced imaging in EORTC clinical trials. The group focuses on the development of specific analytical and review procedures as well as quality control procedures, in the context of clinical trials conducted by the EORTC groups.
doi:10.1016/s1359-6349(12)70015-0 fatcat:ehrha5i7crfqlils3ef4xg64ja

Radio(chemo)therapy in locally advanced nonsmall cell lung cancer

Markus Glatzer, Olgun Elicin, Sara Ramella, Ursula Nestle, Paul Martin Putora
2016 European Respiratory Review  
Definitive radiochemotherapy is the standard treatment for many patients with locally advanced nonsmall cell lung cancer (NSCLC). Treatment outcomes have improved over the last decades. Several treatment regimens have been shown effective and safe. This review summarises the results of significant studies between 1996 and 2015 on concomitant and sequential radiochemotherapy regimens and radiation dose per fraction. Beside therapy regimens, optimised radiotherapy planning is indispensable to
more » ... ove outcome and minimise radiation-induced toxicity. An insight into the rationale of radiotherapy planning for stage III NSCLC is also provided. @ERSpublications Concomitant radiochemotherapy is an established standard treatment for locally advanced nonsmall cell lung cancer http://ow.ly/TTkkc Staging An essential part of lung cancer staging is proper mediastinal lymph node staging, which may be achieved by fine needle aspiration (e.g. endobronchial ultrasound guided biopsies, transoesophageal biopsies), mediastinoscopy, 18-fluorodeoxyglucose positron emission tomography or a combination of these. When mediastinal lymph nodes are limited to the ipsilateral mediastinum, it is considered N2 (stage IIIA: T1-3 N2 or T4 N1) disease, while contralateral involvement denotes N3 disease (stage IIIB: T1-3 N3 or T4 N2). While stage IIIB N3 is generally not amenable to surgery [3], certain subsets of stage IIIA N2 disease are approachable with surgery. To help differentiate, the American College of Chest Physicians has published
doi:10.1183/16000617.0053-2015 pmid:26929423 fatcat:cnvc4zjqn5btno2nykoxp3w3um

Evolving target volume concepts in locally advanced non-small cell lung cancer

Ursula Nestle, Cecile Le Pechoux, Dirk De Ruysscher
2021 Translational Lung Cancer Research  
Radiotherapy (RT) target volume concepts for locally advanced lung cancer have been under discussion for years. Although they may be as important as treatment doses, many aspects of them are still based on conventions, which, due to the paucity of prospective data, rely on long-term practice or on clinical knowledge and experience (e.g., on patterns of spread or recurrence). However, in recent years, large improvements have been made in medical imaging and molecular imaging methods have been
more » ... lemented, which are of great interest in RT. For lung cancer, in recent years, 18F-fluoro-desoxy-glucose (FDG)-positron-emission tomography (PET)/computed tomography (CT) has shown a superior diagnostic accuracy as compare to conventional imaging and has become an indispensable standard tool for diagnostic workup, staging and response assessment. This offers the chance to optimize target volume concepts in relation to modern imaging. While actual recommendations as the EORTC or ESTRO-ACROP guidelines already include imaging standards, the recently published PET-Plan trial prospectively investigated conventional versus imaging guided target volumes in relation to patient outcome. The results of this trial may help to further refine standards. The current review gives a practical overview on procedures for pre-treatment imaging and target volume delineation in locally advanced non-small cell lung cancer (NSCLC) in synopsis of the procedures established by the PET-Plan trial with the actual EORTC and ACROP guidelines.
doi:10.21037/tlcr-20-805 pmid:34012809 pmcid:PMC8107754 fatcat:lpe4gxohzfhfnabkwy5mjf27ju

Radiotherapy and COVID-19—everything under control or just the start of a long story?

Ursula Nestle, Mechthild Krause
2020 Strahlentherapie und Onkologie (Print)  
Nestle and M. Krause declare that they have no competing interests.  ... 
doi:10.1007/s00066-020-01704-x pmid:33231738 fatcat:ymccytq3rrfwpdd5pumvfijerm

Practice recommendations for lung cancer radiotherapy during the COVID-19 pandemic: An ESTRO-ASTRO consensus statement

Esther G.C. Troost, Ursula Nestle, Paul Martin Putora, Johan Bussink
2020 Radiotherapy and Oncology  
doi:10.1016/j.radonc.2020.04.030 pmid:32342862 pmcid:PMC7194725 fatcat:yrpr5fvv3zcgphu6ukt6k4ip7q

Stereotactic body radiotherapy (SBRT) for locally advanced intrahepatic and extrahepatic cholangiocarcinoma

Eleni Gkika, Lukas Hallauer, Simon Kirste, Sonja Adebahr, Nico Bartl, Hannes Philipp Neeff, Ralph Fritsch, Volker Brass, Ursula Nestle, Anca Ligia Grosu, Thomas Baptist Brunner
2017 BMC Cancer  
To evaluate the role of ablative radiotherapy doses in the treatment of hilar or intrahepatic cholangiocarcinoma (CCC) using stereotactic body radiotherapy (SBRT). Methods: Consecutive patients treated from 2007 to 2016 with CCC were evaluated. Local control and toxicities were assessed every 3 months according to the Response Evaluation Criteria In Solid Tumors (RECIST) and the Common Terminology Criteria for Adverse Events v4.0, respectively. Overall survival (OS), local control (LC) and
more » ... ession free survival were calculated from SBRT. Results: Thirty seven patients with 43 lesions were retrospectively evaluated. The median dose delivered was 45 Gy (range 25-66 Gy) in 3-12 fractions, corresponding to a median equivalent dose in 2 Gy fractions (EQD2 10 ) of 56 (range 25-85) Gy. The median follow up was 24 months. The OS at 1 year was 56% with a median OS of 14 (95% CI: 7.8-20.2) months from start of SBRT and 22 (95% CI: 17.5-26.5) months from diagnosis. Eight lesions progressed locally. The local control rate (LC) at 1 year was 78%. The median progression free survival was 9 months (95% CI 2.8-15.2) 21 patients progressed in the liver but out of field and 15 progressed distantly. SBRT was well tolerated. Three patients (9%) developed a Grade III bleeding. Seven patients developed a cholangitis, one due to progression and the other because of a stent dysfunction 2-21(median 8) months from SBRT. Conclusion: In patients with locally advanced cholangiocarcinoma, SBRT is a local treatment option with an acceptable toxicity profile which warrants further investigation in prospective trials.
doi:10.1186/s12885-017-3788-1 pmid:29162055 pmcid:PMC5699184 fatcat:okroy5laffekfiu44qbsocw7ba

Visualization of 4D multimodal imaging data and its applications in radiotherapy planning

Matthias Schlachter, Tobias Fechter, Sonja Adebahr, Tanja Schimek-Jasch, Ursula Nestle, Katja Bühler
2017 Journal of Applied Clinical Medical Physics  
Fechter T, Carles M, Chirindel A, Christ U, Nestle U. A threshold and region-growing based algorithm for 18FDG-PET 4D GTV delineation.  ...  MacManus M, Nestle U, Rosenzweig KE, et al. Use of PET and PET/ CT for radiation therapy planning: IAEA expert report 2006-2007. Radiother Oncol. 2009;91:85-94.  ... 
doi:10.1002/acm2.12209 pmid:29082656 pmcid:PMC5689910 fatcat:4o33mkomkrgmrdheziumblnxue

Excellent local control and tolerance profile after stereotactic body radiotherapy of advanced hepatocellular carcinoma

Eleni Gkika, Michael Schultheiss, Dominik Bettinger, Lars Maruschke, Hannes Philipp Neeff, Michaela Schulenburg, Sonja Adebahr, Simon Kirste, Ursula Nestle, Robert Thimme, Anca-Ligia Grosu, Thomas Baptist Brunner
2017 Radiation Oncology  
To evaluate the efficacy and toxicity of stereotactic body radiotherapy (SBRT) in the treatment of advanced hepatocellular carcinoma (HCC). Material and Methods: Patients with large HCCs (median diameter 7 cm, IQR 5-10 cm) with a Child-Turcotte-Pugh (CTP) score A (60%) or B (40%) and Barcelona-Clinic Liver Cancer (BCLC) classification stage B or C were treated with 3 to 12 fractions to allow personalized treatment according to the size of the lesions and the proximity of the lesions to the
more » ... s at risk aiming to give high biologically equivalent doses assuming an α/β ratio of 10 Gy for HCC. Primary end points were in-field local control and toxicity assessment. Results: Forty seven patients with 64 lesions were treated with SBRT (median 45 Gy in 3-12 fractions) with a median follow up for patients alive of 19 months. The median biological effective dose was 76 Gy (IQR 62-86 Gy). Tumor vascular thrombosis was present in 28% and an underlying liver disease in 87% (hepatitis B or C in 21%, alcohol related in 51%, nonalcoholic steatohepatitis in 13% of the patients, primary biliary cirrhosis 2%). Eighty three percent received prior and in most cases multiple therapies. Local control at 1 year was 77%. The median overall survival from the start of SBRT was 9 months (95% CI 7.7-10.3). Gastrointestinal toxicities grade ≥ 2 were observed in 3 (6.4%) patients. An increase in CTP score without disease progression was observed in 5 patients, of whom one patient developed a radiation induced liver disease. One patient died due to liver failure 4 months after treatment. Conclusion: SBRT is an effective local ablative therapy which leads to high local control rates with moderate toxicity for selected patients with large tumors.
doi:10.1186/s13014-017-0851-7 pmid:28701219 pmcid:PMC5508695 fatcat:wec7xbbenbfjtp7imwirxm5pce

Using GOMS and NASA-TLX to Evaluate Human–Computer Interaction Process in Interactive Segmentation

Anjana Ramkumar, Pieter Jan Stappers, Wiro J. Niessen, Sonja Adebahr, Tanja Schimek-Jasch, Ursula Nestle, Yu Song
2016 International Journal of Human-Computer Interaction  
HCI plays an important role in interactive medical image segmentation. The Goals, Operators, Methods, and Selection rules (GOMS) model and the National Aeronautics and Space Administration Task Load Index (NASA-TLX) questionnaire are different methods that are often used to evaluate the HCI process. In this article, we aim at improving the HCI process of interactive segmentation using both the GOMS model and the NASA-TLX questionnaire to: 1) identify the relations between these two methods and
more » ... ) propose HCI design suggestions based on the synthesis of the evaluation results using both methods. For this, we conducted an experiment where three physicians used two interactive segmentation approaches to segment different types of organs at risk for radiotherapy planning. Using the GOMS model, we identified 16 operators and 10 methods. Further analysis discovered strong relations between the use of GOMS operators and the results of the NASA-TLX questionnaire. Finally, HCI design issues were identified, and suggestions were proposed based on the evaluation results and the identified relations.
doi:10.1080/10447318.2016.1220729 fatcat:h332rpzesnc47cnrfkma37rnka

Lungtech, a phase II EORTC trial of SBRT for centrally located lung tumours – a clinical physics perspective

Marie Lambrecht, Christos Melidis, Jan-Jakob Sonke, Sonja Adebahr, Ronald Boellaard, Marcel Verheij, Matthias Guckenberger, Ursula Nestle, Coen Hurkmans
2016 Radiation Oncology  
The EORTC has launched a phase II trial to assess safety and efficacy of SBRT for centrally located NSCLC: The EORTC 22113-08113-Lungtech trial. Due to neighbouring critical structures, these tumours remain challenging to treat. To guarantee accordance to protocol and treatment safety, an RTQA procedure has been implemented within the frame of the EORTC RTQA levels. These levels are here expanded to include innovative tools beyond protocol compliance verification: the actual dose delivered to
more » ... ch patient will be estimated and linked to trial outcomes to enable better understanding of dose related response and toxicity. Method: For trial participation, institutions must provide a completed facility questionnaire and beam output audit results. To insure ability to comply with protocol specifications a benchmark case is sent to all centres. After approval, institutions are allowed to recruit patients. Nonetheless, each treatment plan will be prospectively reviewed insuring trial compliance consistency over time. As new features, patient's CBCT images and applied positioning corrections will be saved for dose recalculation on patient's daily geometry. To assess RTQA along the treatment chain, institutions will be visited once during the time of the trial. Over the course of this visit, end-toend tests will be performed using the 008ACIRS-breathing platform with two separate bodies. The first body carries EBT3 films and an ionization chamber. The other body newly developed for PET-CT evaluation is fillable with a solution of high activity. 3D or 4D PET-CT and 4D-CT scanning techniques will be evaluated to assess the impact of motion artefacts on target volume accuracy. Finally, a dosimetric evaluation in static and dynamic conditions will be performed. Discussion: Previous data on mediastinal toxicity are scarce and source of cautiousness for setting-up SBRT treatments for centrally located NSCLC. Thanks to the combination of documented patient related outcomes and CBCT based dose recalculation we expect to provide improved models for dose response and dose related toxicity. Conclusion: We have developed a comprehensive RTQA model for trials involving modern radiotherapy. These procedures could also serve as examples of extended RTQA for future radiotherapy trials involving quantitative use of PET and tumour motion.
doi:10.1186/s13014-015-0567-5 pmid:26791788 pmcid:PMC4721147 fatcat:b76ncbp3mzap7binpoj4wng2i4
« Previous Showing results 1 — 15 out of 628 results